[go: up one dir, main page]

US3878213A - Certain 4-(n-pyrimidin-2-ylsulfamoyl)-phenylacetamides - Google Patents

Certain 4-(n-pyrimidin-2-ylsulfamoyl)-phenylacetamides Download PDF

Info

Publication number
US3878213A
US3878213A US288590A US28859072A US3878213A US 3878213 A US3878213 A US 3878213A US 288590 A US288590 A US 288590A US 28859072 A US28859072 A US 28859072A US 3878213 A US3878213 A US 3878213A
Authority
US
United States
Prior art keywords
sulfamoyl
pyrimidinyl
compound
phenylacetic acid
sulfamoylpyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US288590A
Inventor
Hanns Ahrens
Helmut Biere
Clemens Rufer
Wolfgang Felix Losert
Olaf Loge
Ekkehard Schillinger
Eberhard Schroder
Erich Gerhards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2150279A external-priority patent/DE2150279C2/en
Application filed by Individual filed Critical Individual
Priority to US288590A priority Critical patent/US3878213A/en
Application granted granted Critical
Publication of US3878213A publication Critical patent/US3878213A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Definitions

  • ABSTRACT Compounds of the formula N-CO-C Rl/ a SOZ-NH- N R".
  • R is l-tetrahydronaphthyl, 1 -indan yl, l-a-naphthylethyl, l-(2-pyridyl)-etheyl, l-phenyl-2,2,Z-trifluoroethyl, l-cyanobenzyl, 1-( 2-phenyl )-phenylethyl, or l-(N-methyl-3-indolyl)-ethyl;
  • R is hydrogen
  • R and R jointly with the connecting nitrogen atom are 2-methylindolyl
  • R" is isobutyl, neopentyl, or i-propoxy
  • C* is an axymmetric carbon atom
  • A is a monocyclic aromatic ring which may contain two substitutents R and R X and Y are equal or different and each constitute a direct bond or methylene,
  • R and R are different and are hydrogen, straightchained or branched alkyl having up to 4 carbon atoms, carboxyl or alkoxycarbonyl having up to 4 carbon atoms in the alkoxy group, R and R are equal or different and are hydrogen or alkyl having up to 4 carbon atoms, R is straight chained or branched alkyl having up to 6 carbon atoms, and
  • W is a direct CC bond, oxygen, or sulfur, and their salts with physiologically tolerated bases.
  • These compounds are suitable for treatment of diabetes mellitus.
  • R is hydrogen
  • R and R jointly with the connecting nitrogen atom are 2-methylindoyl
  • R is isobutyl neopentyl or i-propoxy, and salts of said sulfamoylpyrimidines with physiologically tolerated bases.
  • the tests for blood sugar level is performed hourly for six hours on a rabbit having fasted for 24 hours.
  • the lowest dosage for example of 4-[N-(5-isobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid l-anaphthylethylamide which lowers the blood sugar level as strongly as 1 mg/kg 4-[N-(5-isopropoxy-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid 5-chloro-2- methoxyanilide, one of the most effective compounds. disclosed in Belgian Patent No.
  • the compounds of the invention may be administered orally as the free sulfonamides, as salts with physiologically tolerated inorganic and/or organic bases, such as sodium, lithium, calcium, ammonium hydroxides, amines such as methylglucamine, morpholine, ethanolamine, and the like, also in the form of mixtures of the free sulfonamides with a suitable alkali metal carbonate or bicarbonate.
  • physiologically tolerated inorganic and/or organic bases such as sodium, lithium, calcium, ammonium hydroxides, amines such as methylglucamine, morpholine, ethanolamine, and the like, also in the form of mixtures of the free sulfonamides with a suitable alkali metal carbonate or bicarbonate.
  • the acid was converted to the acyl chloride with thionyl chloride, and 19 mM of the acyl chloride were reacted with 28 mM (S)-la-naphthylethylamine and 20 mM triethylamine in 100 ml chloroform at boiling heat in 1 hour.
  • the solvent was evaporated, the residue was suspended in dilute hydrochloric acid, and sequentially recrystallized from pyriding-water mixture and isopropanolacetone-water.
  • EXAMPLE 7 4-[ N-( 5 -lsobutyl-2-p yrimidinyl )-sulfamoyl 1- phenylacetic acid+l 2-pyridyl)-ethylamide
  • the compound was prepared by analogy with Example 1 from l-(2-pyridyl)-ethylamine. However, the ace tone was distilled off, the residue was suspended in dilute hydrochloric acid and extracted with chloroform. The residue obtained after evaporation of the chloroform was taken up in aqueous sodium bicarbonate solution, the mixture was filtered, the filtrate was acidified, and the precipitate formed thereby was filtered off with suction and taken up in aqueous ammonia. The solution was filtered over charcoal and acidified to pH 6 with 20% acetic acid. The precipitate was recrystallized from ethanol-water.
  • EXAMPLE 8 4-[N-(5-Isobutyl-2-pyrimidiny1)-sulfamoyl]- phenylacetic acid 1 -phenyl-2-2,2-trifluoroethylamide
  • the compound was prepared by analogy with Example 1 using 1-phenyl-2,2,2-trifluoroethylamine. Yield; 30% of theory. melting point: 168 C.
  • EXAMPLE l0 4-[N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl]- phenylacetic acid l-(2-phenyl)-phenylethylamide
  • EXAMPLE 1 l 4-[N-(5-Neopentyl-2-pyrimidinyl )-sulfamoyl]- phenylacetic acid 1-(N-methyl-3-indolyl)-ethylamide The compound was prepared according to Example 1 from l-(l-methyl-3-indolyl)-ethylamine.
  • EXAMPLE l2 4-[N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl]- phenylacetic acid 2-methylindolinide
  • the compound was prepared according to Example 1 from Z-methylindoline. Yield: 40% of theory. Melting point: 171 C (hydrate).
  • sulfamoylpyrimidine is 4-[N-(5-Isobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic dronaphthylamide.
  • a compound as set forth in claim 1, wherein said acid- 1 -tetrahysulfamoylpy rimidine is 4-[ N 5-lsobutyl-2- pyrimidinyl )-sulfamoyll-phenylacetic acid 1- indanylamide.
  • sulfamoylpyrimidine is R(+)-4-[N-(5-lsobutyl -2- pyrimidinyl)-sulfamoyl]-phenylacetic acid- 1 -oznaphthylethylamide.
  • a compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-[N-(5-lsobutyl-2- pyrimidin yl )-sulfamoyl -phenylacetic acid- 1 -p henyl- 2,2,2-trifluoroethylamide.
  • a compound as set forth in claim 1, wherein said acid- 1 2- sulfamoylpyrimidine is 4-[N-( 5-Isobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid-l-cyanobenzylamide.
  • a compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-[N-(5-lsobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid l-(2- phenyl)-phenylethylamide.
  • a compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-[N-(5-Neopentyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid l-(N- methyl-3-indolyl )-ethylamide.
  • a compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4- N-( 5 -lsobutyl-2- pyrimidinyl )-sulfamoyl -phenylacetic acid 2 methylindolinide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the formula

WHEREIN R is 1-tetrahydronaphthyl, 1-indanyl, 1- Alpha -naphthylethyl, 1-(2-pyridyl)-etheyl, 1-phenyl-2,2,2-trifluoroethyl, 1cyanobenzyl, 1-(2-phenyl)-phenylethyl, or 1-(N-methyl-3indolyl)-ethyl; R'' is hydrogen; or R and R'' jointly with the connecting nitrogen atom are 2methylindolyl; and R'''' is isobutyl, neopentyl, or i-propoxy, AND THEIR SALTS WITH PHYSIOLOGICALLY TOLERATED BASES LOWER THE BLOOD SUGAR LEVEL IN DIABETES MELLITUS.

Description

United States Patent [191 Ahrens et al.
[451 Apr. 15, 1975 CERTAIN 4-(N-PYRIMlDIN-2-YLSULFAMOYL)- PHENYLACETAMIDES [76] Inventors: Hanns Ahrens, Spanische Allee 72a,
1 Berlin 38; Helmut Biere, Joachim-Friedrich-Str. 13, 1 Berlin 31; Clemens Rufer, 38 Lagardestr. 44a, 1 Berlin 38; Wolfgang Felix Losert, Maximilankorso 20, 1 Berlin 28; Olaf Loge, Hauptstr. 118, 1 Berlin 62; Ekkehard Schillinger, Bekassinenweg, 37, 1 Berlin 27; Eberhard Schriider, Am Rosenanger 22, Berlin 28; Erich Gerhards, Cimbernstr. 6, Berlin 38, all of Germany 9 [22] Filed: Sept. 13, 1972 [21] Appl. No.: 288,590
Related US. Application Data [63] Continuation-in-part of Ser. No. 129,948, March 31,
1971, abandoned.
[30] Foreign Application Priority Data Oct. 5, 1971 Germany 2150279 [52] US. Cl 260/256.5 R; 260/247.1; 424/251 [51] Int. Cl C07d 51/42 [58] Field of Search 260/256.5 R
[56] References Cited UNITED STATES PATENTS 3,621,026 11/1971 Gutsche et al. 260/256.5 R
Primary ExaminerR. J. Gallagher Attorney, Agent, or Firm-Joseph F. Padlon [57] ABSTRACT Compounds of the formula N-CO-C Rl/ a SOZ-NH- N R".
wherein R is l-tetrahydronaphthyl, 1 -indan yl, l-a-naphthylethyl, l-(2-pyridyl)-etheyl, l-phenyl-2,2,Z-trifluoroethyl, l-cyanobenzyl, 1-( 2-phenyl )-phenylethyl, or l-(N-methyl-3-indolyl)-ethyl;
R is hydrogen; or
R and R jointly with the connecting nitrogen atom are 2-methylindolyl; and
R" is isobutyl, neopentyl, or i-propoxy,
and their salts with physiologically tolerated bases lower the blood sugar level in diabetes mellitus.
13 Claims, N0 Drawings CERTAIN 4-(NJZYRIDIMIN-2-YLSULFAMOYL)- I PHENYLACETAMIDES This application.isa'continuation in part of our copending application Ser. No. 129,948 filed Mar. 31, 1971 now abandoned.
In the parent application Ser. No; 129,948, there were disclosed compounds of the formula wherein:
C* is an axymmetric carbon atom,
A is a monocyclic aromatic ring which may contain two substitutents R and R X and Y are equal or different and each constitute a direct bond or methylene,
R and R are different and are hydrogen, straightchained or branched alkyl having up to 4 carbon atoms, carboxyl or alkoxycarbonyl having up to 4 carbon atoms in the alkoxy group, R and R are equal or different and are hydrogen or alkyl having up to 4 carbon atoms, R is straight chained or branched alkyl having up to 6 carbon atoms, and
W is a direct CC bond, oxygen, or sulfur, and their salts with physiologically tolerated bases.
These compounds are suitable for treatment of diabetes mellitus.
It has now been found that a strong lowering effect on the blood sugar level is also produced by sulfamoylpyrimidines of the formula wherein I R is l-tetrahydronaphthyl, l-indanyl, l-anaphthylethyl, l-(2-pyridyl)-ethyl, 1-phenyl-2,2,2-
trifluoroethyl, l-cyanobenzyl, 1-(2-phenyl)- I phenylethyl, or 1-(N-methyl-3-indolyl)-ethyl;
R is hydrogen; or
R and R jointly with the connecting nitrogen atom are 2-methylindoyl; and
R is isobutyl neopentyl or i-propoxy, and salts of said sulfamoylpyrimidines with physiologically tolerated bases.
The tests for blood sugar level is performed hourly for six hours on a rabbit having fasted for 24 hours. The lowest dosage, for example of 4-[N-(5-isobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid l-anaphthylethylamide which lowers the blood sugar level as strongly as 1 mg/kg 4-[N-(5-isopropoxy-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid 5-chloro-2- methoxyanilide, one of the most effective compounds. disclosed in Belgian Patent No. 726,253, is near 3 for the form, and near 0.1 for the form (tested dosage levels being: 30, 3, 1, 05,025, 0.1 0.05 mg/kg). It is surprisingjthat the increase in the blood sugar ilevel lowering effect is broug'ht'about by achange "of the molecule in the extended side chain of the sulfonated benz'ene nucleus, that is, in a location which does not necessarily relate to the fi-zytotrop'ic effect of the sulfonamides, since even compounds having no side chains, such as Glymidin, have B-zytotropic effect.
For their therapeutic use, the compounds of the invention may be administered orally as the free sulfonamides, as salts with physiologically tolerated inorganic and/or organic bases, such as sodium, lithium, calcium, ammonium hydroxides, amines such as methylglucamine, morpholine, ethanolamine, and the like, also in the form of mixtures of the free sulfonamides with a suitable alkali metal carbonate or bicarbonate. Bases which themselves lower the blood sugar level, such as EXAMPLE 1 4-'[N-(S-Isobutyl-Z-pyrimidinyl)-sulfamoyl]- phenylacetic acid l-tetrahyd ronaphthylam ide A solution of 22 millimole (mM) triethylamine and 22 mM l-aminotetrahydronaphthalene in 30 ml acetone was added dropwise to a solution of 20 mM 4-[N- (5-isobutyl-2-pyrimidinyl)-sulfamoyl]-phenylacetyl chloride in m1 acetone. The'mixt'ure was held for 16 hours at 20 C, then heated to a boil for minutes, cooled, and filtered with suction. The recovered solid was recrystallized from ethanol.
Yield: 4.5 g of melting point 174 C.
EXAMPLE 2 4-[N-(5-lsobutyl-2-pyrimidinyl)-sulfamoyl]- phenylacetic acid l-indanylamide The compound was prepared in a manner analogous to Example 1 from l-aminoindane. Yield: 5.8 g of melting point 154 C.
. EXAMPLE 3 R(+)-4-[N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl]- phenylacetic acid l-a-naphthylethylamide The compound was prepared as in Example 1 using R(+)-l-a-naphthylethylamine, and recrystallized from acetone-water mixture 1:1.
Yield: 3.7 g of melting point 172 C. [0:]D +27 (c=l, chloroform).
EXAMPLE 4 S(-)-4-N -(5-Isobutyl-Z-pyrimidinyl)-sulfamoyl]- phenylacetic acid l-a-naphthylethylamide The compound was prepared as in Example 1 from S()-l-a-naphthylethylamine, and recrystallized from actone/water mixture 1 :1
Yield: 4.0 g of melting point 172 C. [011D 23.7 (c=l, chloroform).
EXAMPLE l-a-naphthylethylamide 2-Amino-5-neopentylpyrimidine was prepared by a procedure generally known for synthesizing 2-amino-5- alkylpyrimidines (Arzneimittelforschung 14 [1964 ]373).
56 Millimoles of the prepared compound were treated with 4-chlorosulfonyl-phenylacetic acid in 100 ml pyridin for 2 hours at 80 C. Aqueous hydrochloric acid was added to form a precipitate in which the dimethylamide moiety was saponified by means of 3% sodium hydroxide solution in 6 hours at a boil. The saponification mixture was filtered hot, and 4-[N-(5- neopentyl-Z-pyrimidinyl)-sulfamoyl]-phenylacetic acid was precipitated with hydrochloric acid from the filtrate and recrystallized from methylglycol/ethanol mixture. It weighed 14.2 g and melted at 250 C. The acid was converted to the acyl chloride with thionyl chloride, and 19 mM of the acyl chloride were reacted with 28 mM (S)-la-naphthylethylamine and 20 mM triethylamine in 100 ml chloroform at boiling heat in 1 hour. The solvent was evaporated, the residue was suspended in dilute hydrochloric acid, and sequentially recrystallized from pyriding-water mixture and isopropanolacetone-water.
The desired product was ultimately obtained in a yield of 46% and melted at 166 C. [a]D 25 (c=l, chloroform).
EXAMPLE 6 S()-4[N-('5-Isopropoxy-2-pyrimidinyl )-sulfamoyl]- phenylacetic acid l-a-naphthylethylamide phenylacetyl chloride and (S)-l-a-naphthylethylamine.
Yield: 43% of theory. Melting point: 183 C.
EXAMPLE 7 4-[ N-( 5 -lsobutyl-2-p yrimidinyl )-sulfamoyl 1- phenylacetic acid+l 2-pyridyl)-ethylamide The compound was prepared by analogy with Example 1 from l-(2-pyridyl)-ethylamine. However, the ace tone was distilled off, the residue was suspended in dilute hydrochloric acid and extracted with chloroform. The residue obtained after evaporation of the chloroform was taken up in aqueous sodium bicarbonate solution, the mixture was filtered, the filtrate was acidified, and the precipitate formed thereby was filtered off with suction and taken up in aqueous ammonia. The solution was filtered over charcoal and acidified to pH 6 with 20% acetic acid. The precipitate was recrystallized from ethanol-water.
Yield: 1.2 g containing 1.4% water. Melting point: 84 C.
EXAMPLE 8 4-[N-(5-Isobutyl-2-pyrimidiny1)-sulfamoyl]- phenylacetic acid 1 -phenyl-2-2,2-trifluoroethylamide The compound was prepared by analogy with Example 1 using 1-phenyl-2,2,2-trifluoroethylamine. Yield; 30% of theory. melting point: 168 C.
EXAMPLE 9 4-[N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl]- phenylacetic acid l-cyanobenzylamide The compound was prepared from 2-phenylglycine nitrile by analogy with Example 1. Yield: 13% of theory. Melting Point: C.
EXAMPLE l0 4-[N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl]- phenylacetic acid l-(2-phenyl)-phenylethylamide EXAMPLE 1 l 4-[N-(5-Neopentyl-2-pyrimidinyl )-sulfamoyl]- phenylacetic acid 1-(N-methyl-3-indolyl)-ethylamide The compound was prepared according to Example 1 from l-(l-methyl-3-indolyl)-ethylamine.
EXAMPLE l2 4-[N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl]- phenylacetic acid 2-methylindolinide The compound was prepared according to Example 1 from Z-methylindoline. Yield: 40% of theory. Melting point: 171 C (hydrate).
We claim:
1. A compound which is a sulfamoylpyrimidine of the formula wherein R is l-tetrahydronaphthyl, l-indanyl, l-anaphthylethyl, l-(2-pyridyl)-ethyl, l-phenyl-2,2,2- trifluoroethyl, l-cyanobenzyl, l-( 2-phenyl)- phenylethyl, or l-(N-methyl-3-indolyl)-ethyl; R is hydrogen, or R and R jointly with the connecting nitrogen atom are Z-methylindolyl; and R" is isobutyl, neopentyl, or isopropoxy; or a salt of said sulfamoylpyrimidine with a physiologically tolerated base.
2. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-[N-(5-Isobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic dronaphthylamide.
3. A compound as set forth in claim 1, wherein said acid- 1 -tetrahysulfamoylpy rimidine is 4-[ N 5-lsobutyl-2- pyrimidinyl )-sulfamoyll-phenylacetic acid 1- indanylamide.
4. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is R(+)-4-[N-(5-lsobutyl -2- pyrimidinyl)-sulfamoyl]-phenylacetic acid- 1 -oznaphthylethylamide.
5. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is ,S(-)-4-[N-(5-Isobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acidl -oznaphthylethylamide.
6 pyrimidinyl )-sulfamoyl] -phenylacetic pyridyl)-ethylamide.
9. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-[N-(5-lsobutyl-2- pyrimidin yl )-sulfamoyl -phenylacetic acid- 1 -p henyl- 2,2,2-trifluoroethylamide.
10. A compound as set forth in claim 1, wherein said acid- 1 2- sulfamoylpyrimidine is 4-[N-( 5-Isobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid-l-cyanobenzylamide.
11. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-[N-(5-lsobutyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid l-(2- phenyl)-phenylethylamide.
12. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-[N-(5-Neopentyl-2- pyrimidinyl)-sulfamoyl]-phenylacetic acid l-(N- methyl-3-indolyl )-ethylamide.
13. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4- N-( 5 -lsobutyl-2- pyrimidinyl )-sulfamoyl -phenylacetic acid 2 methylindolinide.

Claims (13)

1. A COMPOUND WHICH IS A SULFAMOYLPYRIMIDINE OF THE FORMULA
2. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1-tetrahydronaphthylamide.
3. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid 1-indanylamide.
4. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is R(+)-4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1- Alpha -naphthylethylamide.
5. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is S(-)-4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1- Alpha -naphthylethylamide.
6. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is S(-)-4-(N-(5-Neopentyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1- Alpha -naphthylethylamide.
7. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is S(-)-4-(N-(5-Isopropoxy-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1- Alpha -naphthylethylamide.
8. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1-(2-pyridyl)-ethylamide.
9. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1-phenyl-2,2,2-trifluoroethylamide.
10. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid-1-cyano-benzylamide.
11. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid 1-(2-phenyl)-phenylethylamide.
12. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Neopentyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid 1-(N-methyl-3-indolyl)-ethylamide.
13. A compound as set forth in claim 1, wherein said sulfamoylpyrimidine is 4-(N-(5-Isobutyl-2-pyrimidinyl)-sulfamoyl)-phenylacetic acid 2''-methylindolinide.
US288590A 1971-03-31 1972-09-13 Certain 4-(n-pyrimidin-2-ylsulfamoyl)-phenylacetamides Expired - Lifetime US3878213A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US288590A US3878213A (en) 1971-03-31 1972-09-13 Certain 4-(n-pyrimidin-2-ylsulfamoyl)-phenylacetamides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12994871A 1971-03-31 1971-03-31
DE2150279A DE2150279C2 (en) 1971-10-05 1971-10-05 Blood sugar lowering sulfamoylpyrimidines with an asymmetric carbon atom
US288590A US3878213A (en) 1971-03-31 1972-09-13 Certain 4-(n-pyrimidin-2-ylsulfamoyl)-phenylacetamides

Publications (1)

Publication Number Publication Date
US3878213A true US3878213A (en) 1975-04-15

Family

ID=27183769

Family Applications (1)

Application Number Title Priority Date Filing Date
US288590A Expired - Lifetime US3878213A (en) 1971-03-31 1972-09-13 Certain 4-(n-pyrimidin-2-ylsulfamoyl)-phenylacetamides

Country Status (1)

Country Link
US (1) US3878213A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621026A (en) * 1967-12-30 1971-11-16 Schering Ag Of Berlin Blood-sugar-lowering sulfonylamino pyrimidines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621026A (en) * 1967-12-30 1971-11-16 Schering Ag Of Berlin Blood-sugar-lowering sulfonylamino pyrimidines

Similar Documents

Publication Publication Date Title
JP4969238B2 (en) Compounds, compositions and methods
CN104583199B (en) 2-aminopyrazine derivatives as CSF-1R kinase inhibitors
US3161653A (en) 2-[(2'-methyl-benzo-thienyl-3')-methyl]-delta2-imidazoline and its pharmaceutically aceptable acid addition salts
NO892982L (en) TETRAHYDRO-1-benz (C, D) -INDOLPROPIONSYRE sulfonamides.
BRPI0708914A2 (en) 2- (aminocyclic) pyrimidone derivatives
BR112014004741B1 (en) CHEMICAL ENTITY, ITS USE AND PHARMACEUTICAL COMPOSITION INCLUDING IT
CN111434661A (en) Aromatic heterocyclic compound with cell necrosis inhibitory activity and application thereof
JP2531304B2 (en) Novel aminopiperazine derivative
MXPA06002347A (en) Compounds and compositions as protein kinase inhibitors.
MXPA05006385A (en) N-(indolethyl-)cacloamine compounds.
US3668215A (en) Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups
JPWO1991001979A1 (en) Novel aminopiperazine derivatives
JPH05194440A (en) Oxazolidone derivative
US3338899A (en) 3-phenyl-5-amino-1, 2, 4-oxadiazole compounds
US3878213A (en) Certain 4-(n-pyrimidin-2-ylsulfamoyl)-phenylacetamides
US3759911A (en) Triazine derivatives
US3654275A (en) Quinoxalinecarboxamide antiinflammatory agents
US3705151A (en) Benzene-sulfonyl semicarbazides and process for preparing them
US3826791A (en) Heterocyclic amides of 4-hydroxy-2h-1-benzothiopyran-3-carboxylic acid 1,1-dioxide and process for their production
CN102796121B (en) 3-aryl-7H-thiazol[3,2-b]-1,2,4-triazinyl-7-one derivatives and application thereof
US3694450A (en) 2-substituted-4,5,6,7-tetrahydrobenzothiazole-4-carboxylic acids and their alkyl esters
JPH09502433A (en) Polyamino acid derivative having anti-gastrin activity, its production method and pharmaceutical use
NO145651B (en) MACHINE FOR CASTING CONCRETE PIPES IN STANDING POSITION.
US3234219A (en) 5-nitro-furyl-(2)-methylidene hydrazides
US2592931A (en) Thiothiazolone derivatives